ImmunoGeneSB Advisory operates at the razor's edge of biotechnological discovery. We dismantle the silos between high-stakes clinical research and strategic capital allocation — providing research-grade rigor to a market often obscured by noise. Our analysis is not a forecast; it is a deconstruction of molecular evidence.
Our clients don't hire a brand — they hire deep scientific competence. We let our expertise speak for itself. Here is what our team brings to every engagement.
Senior scientist with over 12 years of experience in cell biology, immunology, and hematopoietic models, with strong expertise in flow cytometry, gene editing, and in vivo mouse models. Completed postdoctoral training in 2017 and has continued active research to the present.
Scientist with academic training in biology and immunology (BSc and MSc), graduate-level bioinformatics coursework (DESS, 3 semesters at UQAM), and 2 years of hands-on research experience, primarily focused on CAR-NK and CAR-T cell engineering, including cytokine armoring (e.g., IL-15 expression) and targeted gene knockouts, applied to cell-based immunotherapies.
Together, our team covers the full spectrum of modern biotherapeutic development — from gene-level engineering to in vivo validation — giving our clients an unmatched analytical advantage.
We don't sell optimism. We deliver evidence.